For childhood cancer survivors, the transplant may save a life while quietly costing centimeters — a trade-off that has received surprisingly little rigorous attention. Growth impairment is one of the most prevalent late effects following hematopoietic cell transplantation (HCT) in children, yet evidence guiding growth hormone (GH) replacement in this population has remained thin. This nationwide Japanese cohort study is among the most thorough attempts yet to quantify whether GH therapy actually closes that height deficit over the long term.

Across 171 childhood HCT survivors with documented final adult height data, 58 received GH therapy. GH-treated patients achieved meaningfully greater improvements in final height standard deviation scores (SDS) compared to untreated peers, but the response was far from uniform. Three factors independently predicted worse height outcomes regardless of treatment: receipt of total body irradiation (TBI), transplantation before age five, and the presence of chronic graft-versus-host disease. Notably, the variables predicting GH responsiveness differed depending on transplant type, suggesting that a one-size-fits-all treatment algorithm is unlikely to be appropriate. Growth trajectories were tracked at one year, five years, and final height, providing a longitudinal picture rarely captured in prior literature.

This study is clinically valuable but carries important constraints. Its retrospective multicenter design introduces heterogeneity in treatment protocols, and the cohort of 58 GH-treated individuals limits statistical power for subgroup conclusions. The finding that TBI and very young transplant age undermine height outcomes aligns with established radiobiology — hypothalamic-pituitary axis damage from cranial radiation is well documented — but the interaction with chronic graft-versus-host disease adds a layer of complexity that warrants prospective investigation. For pediatric endocrinologists managing HCT survivors, the data support early GH evaluation, particularly in TBI-exposed patients, while tempering expectations for full height normalization in the highest-risk subgroups. This is confirmatory and incrementally advancing rather than paradigm-shifting, but fills a meaningful evidence gap in post-transplant survivorship care.